You are here: Industry Insights > Novavax

News List

Novavax Covid-19 vaccine provides cross-protection against B.1.351 variant pharmaceutical-technology
May 07, 2021
The protein-based vaccine candidate NVX-CoV2373 is made from the genetic sequence of the first SARS-CoV-2 strain. It is adjuvanted with the company’s saponin-based Matrix-M to boost immune response and neutralising antibodies.
Novel vaccine 77 percent effective in preventing malaria, finds study europeanpharmaceuticalreview
April 28, 2021
The R21 vaccine candidate, when administered with 50mg of adjuvant, was found to be 77 percent effective in preventing malaria in children over 12 months.
Oxford University expands Com-COV2 dose-mixing study with Novavax’s Covid-19 vaccine pharmaceutical-technology
April 16, 2021
The University of Oxford has expanded the Comparing Covid-19 Vaccine Schedule Combinations – Stage 2 (Com-COV2) study to include the Novavax and Moderna vaccines for the disease treatment.
UK trial evaluating ‘mix and match’ COVID-19 vaccine regimens expanded pharmatimes
April 15, 2021
A UK trial evaluating the safety of mixing different COVID-19 vaccines is set to be expanded to include Moderna and Novavax’s respective jabs.
Supply scarcity is delaying full scale production of COVID-19 vaccine: Novavax expresspharma
April 15, 2021
Novavax has pushed back the timeline for hitting its production target of 150 million COVID-19 vaccine doses per month until the third quarter due to supply shortages including bags used to grow cells, a company spokeswoman told Reuters.
Executive Moves: Novavax contractpharma
April 15, 2021
Gale Smith named SVP, Discovery and Pre-Clinical Research and Chief Scientist, and Troy Morgan named SVP, Chief Compliance Officer.
Novavax allows giving COVID-19 vaccine to trial participants on placebo expresspharma
April 07, 2021
Allowing volunteers to crossover to the active vaccine offers them an incentive to continue in the trials even when other authorised vaccines are available.
Novavax commences crossover arms in Covid-19 vaccine trials pharmaceutical-technology
April 06, 2021
Novavax has announced the start of crossover arms in the ongoing phase IIb South African trial and pivotal phase III UK trial of its Covid-19 vaccine candidate NVX-CoV2373.
GSK agrees to support manufacture of Novavax' COVID-19 vaccine pharmatimes
March 30, 2021
GlaxoSmithKline (GSK) has agreed in principle to support manufacturing of up to 60 million doses of Novavax’ COVID-19 vaccine candidate – NVX-CoV2373 – for use in the UK.
Jubilant, Novavax Enter COVID-19 Vaccine Partnership contractpharma
March 30, 2021
Jubilant to provide fill-finish manufacturing services for the production of COVID-19 vaccine candidate NVX-CoV2373.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 14 15 Next page